Innovent Biologics Inc. engages in the research, development, manufacture, and sale of biologic therapies, primarily focusing on oncology, autoimmune, metabolic, and other major diseases. As a pharmaceutical and biotechnology company based in China, Innovent is dedicated to advancing affordable and innovative medications. Its robust pipeline includes monoclonal antibodies and immunotherapy solutions, aiming to address the unmet medical needs globally. Innovent Biologics places significant emphasis on collaborative alliances with global partners to harness cutting-edge technologies and enhance its research capabilities. This asset plays a pivotal role in the healthcare and pharmaceutical sectors, offering potential advancements in treatment that could improve the quality of life for millions. The company's influence extends through its contribution to medical research and its potential impact on global health initiatives.